精神分裂症患者难治性幻听经rTMS临床应答的结构与功能脑生物标志物:一项随机假对照双盲临床试验的研究方案
本研究为一项双盲随机假对照单中心临床试验方案,计划纳入45例伴有难治性幻听的的精神分裂症患者,随机接受主动或假1 Hz rTMS治疗,每天两次、每周5天、持续2周,共20次,刺激左侧颞顶联合区。主要结局为应答者与非应答者基线各向异性分数的差异,同时探索静息态功能MRI等生物标志物。
要点
- 45例难治性幻听精神分裂症患者随机接受主动或假1 Hz rTMS,每天2次、每周5天、共2周。
- 主要结局为基线时应答者与非应答者各向异性分数的差异。
- 将在基线及rTMS结束后3天进行弥散加权成像和静息态功能MRI扫描。
核心结论
- 本研究旨在识别和评估基于MRI的结构与功能生物标志物对精神分裂症患者难治性幻听rTMS临床应答的预测价值。
研究设计与样本
- 双盲随机假对照单中心临床试验方案,计划纳入45例伴有难治性幻听的精神分裂症患者。
- 患者被分配接受主动或假1 Hz rTMS,每天两次、每周5天、持续2周,共20次,刺激左侧颞顶联合区。
主要发现
- 主要结局指标为基线时应答者与非应答者之间各向异性分数的差异。
- 还将探究基线时应答者与非应答者之间静息态功能MRI数据的差异。
- 将在基线、rTMS后3天、1个月和3个月进行临床、神经心理、神经生理和血清BDNF评估。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The potential of non-invasive repetitive transcranial magnetic stimulation (rTMS) to improve auditory verbal hallucinations (AVH) in schizophrenia patients has been increasingly explored over the past decade. Despite highly promising results, high inter-individual variability of clinical response and ineffective outcomes in a significant number of patients underscored the need to identify factors associated with the clinical response to rTMS. It should help improve the efficacy of rTMS in patients with medication-resistant AVH, and allow a better understanding of its neural impact. Here, we describe an exploratory study protocol which aims to identify structural and functional brain biomarkers associated with clinical response after an rTMS treatment for medication-resistant AVH in schizophrenia. METHODS: Forty-five schizophrenia patients with medication-resistant AVH will be enrolled in a double-blind randomized sham-controlled monocentric clinical trial. Patients will be assigned to a regime of 20 sessions of active or sham 1 Hz rTMS delivered twice a day, 5 days a week for 2 weeks over the left temporo-parietal junction. Response will be assessed after rTMS and patients will be classified in responders or non-responders to treatment. Magnetic resonance imaging (MRI) sessions including diffusion weighted imaging and resting-state functional MRI sequences will be recorded before the onset of the rTMS treatment and 3 days following its discontinuation. The primary outcome measure is difference in fractional anisotropy between responder and non-responder patients at baseline. Differences in resting-state functional MRI data at baseline will be also investigated between responder and non-responder groups. Clinical, neuropsychological, neurophysiological, and blood serum BDNF assessments will be performed at baseline, 3 days, 1 month, and 3 months following rTMS. DISCUSSION: The aim of this research project is to identify and assess the biomarker value of MRI-based structural and functional biomarkers predicting clinical response to rTMS for AVH in schizophrenia patients. The outcome of the trial should improve patient care by offering them a novel suitable therapy and deepen our understanding on how rTMS may impact AVH and develop more effective therapies adapted to individual patient needs. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02755623 . Registered on 22 April 2016.
引用
- Thomas F, Bouaziz N, Gallea C, et al. Structural and functional brain biomarkers of clinical response to rTMS of medication-resistant auditory hallucinations in schizophrenia patients: study protocol for a randomized sham-controlled double-blind clinical trial. Trials. 2019. PMID: 31014369. doi:10.1186/s13063-019-3311-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。